Our previous study found that plate factor-4 variant (CXCL4L1) was downregulated in the serum of patients with prostate cancer (PCa). The aim of the present study was to investigate the prognostic value of CXCL4L1 in ...Our previous study found that plate factor-4 variant (CXCL4L1) was downregulated in the serum of patients with prostate cancer (PCa). The aim of the present study was to investigate the prognostic value of CXCL4L1 in PCa. In total, 213 PCa patients treated with radical prostatectomy were enrolled and peripheral blood samples of all patients were collected. Expression of serum CXCL4L1 in patients with different tumor stages and grades were measured by enzyme-linked immunosorbent assay (ELISA). The Kaplan-Meier method was applied to estimate the progression to castration-resistant prostate cancer (CRPC), metastasis, biochemical recurrenee (BCR)-free survival, and overall survival (OS). Prog no stic factors for BCR-free survival and OS were determi ned by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of CXCL4L1 was significantly lower in PCa patie nts with adva need pathological tumor stage, high-grade Gleason score, and metastasis. Moreover, down regulation of CXCL4L1 not only strongly correlated with aggressive clinicopathological features, but also predicted tumor progress!on and unfavorable outcomes. Finally, multivariate Cox regression analyses identified CXCL4L1 as an independent prognostic factor for both BCR-free survival (hazard ratio [HR]: 2.03, 95% confidence interval [Cl]: 1.26-3.27;P = 0.004) and OS (HR: 2.26, 95% Cl: 1.07-4.79;P= 0.033). In con elusion, our results in dicate that CXCL4L1 might serve as a no vel and promising prog no stic biomarker for patients with PCa and potential therapeutic target in the future.展开更多
基金the National Natural Science Foundation of China (No. 81600258 and 81802540)the Natural Science Foundation of Liaoning Province (No. 20180550985)the Shenyang Science and Technology Program (No. F15-199-1-47).
文摘Our previous study found that plate factor-4 variant (CXCL4L1) was downregulated in the serum of patients with prostate cancer (PCa). The aim of the present study was to investigate the prognostic value of CXCL4L1 in PCa. In total, 213 PCa patients treated with radical prostatectomy were enrolled and peripheral blood samples of all patients were collected. Expression of serum CXCL4L1 in patients with different tumor stages and grades were measured by enzyme-linked immunosorbent assay (ELISA). The Kaplan-Meier method was applied to estimate the progression to castration-resistant prostate cancer (CRPC), metastasis, biochemical recurrenee (BCR)-free survival, and overall survival (OS). Prog no stic factors for BCR-free survival and OS were determi ned by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of CXCL4L1 was significantly lower in PCa patie nts with adva need pathological tumor stage, high-grade Gleason score, and metastasis. Moreover, down regulation of CXCL4L1 not only strongly correlated with aggressive clinicopathological features, but also predicted tumor progress!on and unfavorable outcomes. Finally, multivariate Cox regression analyses identified CXCL4L1 as an independent prognostic factor for both BCR-free survival (hazard ratio [HR]: 2.03, 95% confidence interval [Cl]: 1.26-3.27;P = 0.004) and OS (HR: 2.26, 95% Cl: 1.07-4.79;P= 0.033). In con elusion, our results in dicate that CXCL4L1 might serve as a no vel and promising prog no stic biomarker for patients with PCa and potential therapeutic target in the future.
